News

Virtune Launches VCOIN50 ETP on Euronext, Expanding Access

Virtune Launches VCOIN50 ETP on Euronext, Expanding Access

Virtune Introduces the Virtune Coinbase 50 Index ETP

Virtune AB, a prominent Swedish regulated crypto asset manager, has triumphantly announced the introduction of its flagship product, the Virtune Coinbase 50 Index ETP (VCOIN50), on Euronext Amsterdam. This highly anticipated exchange-traded product is now accessible for investors within the Netherlands via various brokers and banks, enhancing the product’s reach to a wider audience.

The journey of Virtune has been characterized by a notable demand for digital assets from both institutional and retail investors throughout both the Nordic and European regions. Over the last two years, the company has successfully garnered the trust of more than 140,000 investors, showcasing its commitment to innovative financial solutions. Riding on this upward trend, the listing of VCOIN50 on Euronext marks another significant milestone in Virtune's ambitious expansion strategy across Europe.

Additionally, the VCOIN50 ETP is the first of its kind to track the Coinbase 50 Europe Index, a benchmark developed by Coinbase, an esteemed leader in the global crypto services sector. This product is administered by MarketVector Indexes, a key player in the global indexing space, further solidifying Virtune’s foothold in the crypto investment landscape.

Groundbreaking Features of the VCOIN50 ETP

The introduction of the Virtune Coinbase 50 Index ETP brings several notable firsts to the European financial markets:

  • It is the inaugural ETP to track the Coinbase 50 Europe Index.
  • It stands out as the most comprehensive crypto ETP in Europe, offering exposure to up to 50 diverse crypto assets.

The VCOIN50 ETP is more than just a product; it is a dynamically managed investment vehicle designed with a transparent structure that is backed by physical holdings. This structure is securely maintained through institutional-level custodial solutions, ensuring that investor interests remain safeguarded while providing significant exposure to leading crypto assets.

About the Virtune Coinbase 50 Index ETP

The VCOIN50 ETP is a physically-backed exchange-traded product that tracks the Coinbase 50 Europe Index. This index serves as a premier benchmark for digital assets globally, currently granting exposure to 21 crypto assets that comply with regulatory standards. Virtune aims to expand the ETP to encompass all 50 assets, pending necessary approvals from regulators and stock exchanges.

This ETP not only provides diversified exposure but is also subjected to quarterly rebalancing, which helps maintain alignment with the underlying market conditions, ensuring that it continually meets the evolving demands of investors.

Key Insights into the Product

As of the end of June 2025, the VCOIN50 ETP offers key benefits:

  • Exposure: Access to up to 50 leading crypto assets through a single product.
  • Backing: Fully physically backed by the underlying crypto assets.
  • Custody: Managed with institutional-grade custody through Coinbase.
  • Management Fee: Only 0.95% per annum.
  • Trading Currency: Accessible in both USD and EUR.
  • First Trading Day: Initiated trading on June 30, 2025.
  • Tickers: The product is traded under various tickers including VCOIN50 on Bloomberg and VRTC on Euronext.
  • Regulatory Compliance: Fully compliant and regulated in various European markets.

About Virtune and Its Vision

Virtune is dedicated to delivering innovative investment products that cater to the needs of the evolving digital asset landscape. Since its inception, the firm has prioritized transparency and investor protection, traits that resonate strongly with its growing base of 140,000 customers. Virtune’s rapid growth trajectory is indicative of its successful model, which includes well-structured products and a relentless commitment to educating the market regarding the intricacies of crypto assets and ETPs.

Thoughts from the Leadership

Christopher Kock, the CEO of Virtune, expressed pride in collaborating with Coinbase from the company’s beginnings. He highlighted that the launch of the COIN50 ETP is a significant achievement, catering to a broader European audience eager for robust investment options. He emphasized that the VCOIN50 ETP is designed to mirror the structure and significance of traditional market benchmarks, aiming to become the leading global benchmark for crypto investments.

Coinbase, with its mission of enhancing economic freedom through digital assets, views this partnerships as a leap towards broadening access to institutional-caliber tools for navigating the crypto landscape, thus reinforcing the bridge between traditional financial frameworks and innovative financial products. Brett Tejpaul from Coinbase expressed enthusiasm for the collaborative strides made to ensure that this ETP is readily available to investors across the European Union.

Frequently Asked Questions

What is the Virtune Coinbase 50 Index ETP?

The Virtune Coinbase 50 Index ETP (VCOIN50) is an exchange-traded product designed to give investors exposure to a range of up to 50 crypto assets, tracking the Coinbase 50 Europe Index.

When did the ETP launch on Euronext Amsterdam?

The VCOIN50 ETP began trading on Euronext Amsterdam on June 30, 2025.

How does Virtune ensure investor protection?

Virtune prioritizes transparency and regulation, providing physically-backed products and maintaining a strong commitment to educating investors about market risks.

What are the management fees associated with VCOIN50?

The management fee for the VCOIN50 ETP is 0.95% per annum.

How can investors trade the VCOIN50 ETP?

Investors can trade VCOIN50 through various brokers and banks operating in the Netherlands, making it more accessible for a wider audience.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Updated Category News Views 37

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Continue Reading
Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 127

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 184

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
Bio-Thera's New Data: A Game Changer for NSCLC?

Updated Category News Views 337

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 154

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
Master Sommeliers and Italian Producers Clash on Wine Lists

Updated Category News Views 147

Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...

Continue Reading
Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Updated Category News Views 342

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 342

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 204

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
CapCut's AI Tools Reshape Video Content Creation

Updated Category News Views 143

AI Revolution in Marketing Content: CapCut Takes Lead It's like the old guard of marketing has hitched a ride on a rocket. In 2026, CapCut has stomped into the limelight with Better Business Advice giving them a nod for their prowess in AI-driven content creation. This isn't some passing trend; it's a seismic shift in how businesses craft their messages. CapCut ain't just...

Continue Reading

Top 5 Most Recently Viewed Articles

Genmab's Ongoing Share Buy-back Program Details and Impact

Updated Category News Views 119

Introduction to the Share Buy-back Program In a recent announcement, Genmab A/S (NASDAQ: GMAB) revealed that it has initiated an ambitious share buy-back program. This initiative aims to repurchase up to 2.2 million shares, which is a strategic step not just to reduce capital but also to fulfill commitments under the Restricted Stock Unit program. The company anticipates...

Continue Reading
Allego Strengthens Leadership with New Innovative CTO

Updated Category News Views 159

Allego Appoints Holger Riemenschneider as Chief Technology Officer Allego N.V. (NASDAQ: ALGO) has recently appointed Holger Riemenschneider as its Chief Technology Officer. This move is a significant step for the company, which has rapidly established itself as a leading name in the electric vehicle (EV) charging industry. With Holger on board, Allego is looking to...

Continue Reading
Exploring the Growth Drivers of Semiconductor Fabrication Software

Updated Category News Views 167

Understanding the Semiconductor Fabrication Software Market The Semiconductor Fabrication Software market is on the brink of significant transformation, with projections indicating a remarkable growth of approximately USD 984.91 million from 2024 to 2028. This growth is primarily fueled by the rising complexity of semiconductor designs in conjunction with the impact of...

Continue Reading
Ohmyhome Prepares to Share Exciting Q3 2024 Growth Insights

Updated Category News Views 45

Ohmyhome Set to Unveil Q3 2024 Growth Insights As a leading property technology platform, Ohmyhome Ltd. (NASDAQ: OMH) has established itself as a prominent player in the real estate market. The company specializes in offering comprehensive solutions ranging from brokerage, renovation, and management services for properties in the region. As consumers increasingly look for...

Continue Reading
Eli Lilly Prepares for Major Breast Cancer Data Presentation

Updated Category News Views 220

Introduction to Eli Lilly's Breast Cancer Initiatives At the upcoming San Antonio Breast Cancer Symposium (SABCS), Eli Lilly and Company (NYSE: LLY) is set to unveil groundbreaking data that enhances its portfolio in breast oncology. The symposium, running from December 9 to 12, serves as a platform for Lilly to highlight advancements in treatments for hormone...

Continue Reading